Barbara Domayne Hayman
Mitglied des Investmentausschusses bei Cambridge Enterprise Ltd.
Profil
Barbara Domayne Hayman is currently an Investment Committee member at Cambridge Enterprise Ltd.
and the Chief Business Officer at Autifony Therapeutics Ltd.
She holds a doctorate degree from the University of Oxford.
Aktive Positionen von Barbara Domayne Hayman
| Unternehmen | Position | Beginn |
|---|---|---|
Cambridge Enterprise Ltd.
 Cambridge Enterprise Ltd. Investment ManagersFinance Cambridge Enterprise Ltd.(CEL) is a Venture Capital firm, a subsidiary of University of Cambridge founded in 1972. Headquartered in Cambridge. | Mitglied des Investmentausschusses | - |
Autifony Therapeutics Ltd.
 Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Ausbildung von Barbara Domayne Hayman
| University of Oxford | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Cambridge Enterprise Ltd.
Cambridge Enterprise Ltd. Investment ManagersFinance Cambridge Enterprise Ltd.(CEL) is a Venture Capital firm, a subsidiary of University of Cambridge founded in 1972. Headquartered in Cambridge. | Finance |
Autifony Therapeutics Ltd.
Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | Health Technology |
